Thin film composition

A thin film composition for oral administration of dead/inactivated microorganisms from the Lactobacillaceae family addresses taste and texture issues, offering a convenient and efficient delivery method for digestive health benefits.

WO2026234250A1PCT designated stage Publication Date: 2026-11-12DSM IP ASSETS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063455
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-03
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing digestive postbiotic powders face challenges such as unpleasant taste, texture issues, difficulty in consumption, and potential incompatibility with food or drinks, leading to reduced efficacy and inconvenience in administration, especially for patients with dysphagia.

Method used

A thin film composition is developed for oral administration, comprising dead/inactivated microorganisms from the Lactobacillaceae family, with or without dried fermentation medium, using a formulation that includes film-forming polymers, plasticizers, and emulsifiers, which is designed to dissolve quickly in the mouth, ensuring ease of use and effective delivery.

Benefits of technology

The thin film composition provides a convenient, palatable, and efficient delivery system for health benefits, overcoming taste and texture issues, ensuring complete dosage intake and maintaining efficacy without the need for mixing or swallowing capsules.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
  • Figure IMGF000021_0001_TABLE
    Figure IMGF000021_0001_TABLE
  • Figure IMGF000022_0001_TABLE
    Figure IMGF000022_0001_TABLE
Patent Text Reader

Abstract

The invention relates to a novel thin film composition comprising inanimate cells of microorganisms and their fermentation components that confers a health benefit.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 2025P00129WO (34836- WO- PCT)

[0002] 1

[0003] THIN FILM COMPOSITION

[0004] FIELD OF THE INVENTION

[0005] The invention relates to a novel composition comprising inanimate cells of microorganisms, e.g. from the Lactobacillaceae family, and their fermentation components that confers a health benefit.

[0006] BACKGROUND OF THE INVENTION

[0007] Non-viable microorganisms or fragments thereof and / or microbial cell extracts, mainly heat-killed (including tyndallized) bacteria (e.g. lactic acid bacteria), are able to produce beneficial effects. For example, dead cells of lactic acid bacteria are useful to produce a psychobiotic effect in a human (WO 2019 / 180263), in stimulating the growth of bifidobacteria in the human gut (WO 2021 / 219846) or to treat or prevent an allergic disease (EP-A-2796142).

[0008] The digestive postbiotic powders Lacteol® and Humiome® Post LB, commercially available at dsm-firmenich, both contain heat-treated (inanimate) Lactobacillus LB (combination of Limosilactobacillus fermentum (CNCM I-2998) and Lactobacillus delbrueckii (CNCM 1-4831)) and dried culture medium fermentation including peptides, amino acids, carbohydrates, carbon and minerals. They are used to manage digestive disorders including diarrhoea, restore gut health and improve digestive comfort.

[0009] Powders may be administered in several ways. By direct oral administration, the patient directly consumes the powder by placing it on the tongue and swallowing it with or without water.

[0010] However, patients may find the powder having an unpleasant taste which can make it difficult for patients to consume, or the powdery texture can be so uncomfortable that it may cause gagging or coughing. Alternatively, powders can be mixed with a small amount of food (e.g., applesauce, yogurt) or drink (e.g., water, juice) to mask the taste and make it easier to swallow; the powder may alter the taste of the food or drink, though, making it unpalatable. There may be a risk that the patient may not consume the entire dose if some powder remains in the container or if the food / drink is not fully consumed. In addition, some powders may not dissolve well or may react with certain foods or drinks, affecting the efficacy of the medicine. Another way of oral administration of powders may be in unit dosage form where the powder is pre-measured and packaged in e.g. capsules or sachets, which can be swallowed directly or mixed with water before consumption; however, opening sachets and mixing the powder can be inconvenient and time-consuming or patients with dysphagia or difficulty swallowing may struggle to consume capsules.2025P00129WO (34836- WO- PCT)

[0011] 2

[0012] There is a need for providing an alternative formulation of digestive postbiotic powders that overcomes one of more of the above disadvantages and has proper shelf-life making it suitable to commercialize.

[0013] SUMMARY OF THE INVENTION

[0014] The first aspect of the inventions relates to a thin film composition for oral administration comprising dead / inactivated microorganisms that confer a health benefit on the host.

[0015] Advantageously, the thin film composition also comprises the dried fermentation medium from which the dead / inactivated microorganisms are derived and the medium components therein. Preferably, the thin film composition comprises a composition containing the dead / inactivated microorganism with or without its dried fermentation medium, which is present in 30-50 wt% based on the total weight of the orally applicable thin film composition. In preferred embodiments, the dead / inactivated microorganisms are lactic acid bacteria, more preferably cells from the Lactobacillaceae family, especially comprising or consisting of Limosilactobacillus fermentum and / or Lactobacillus delbrueckii.

[0016] The second aspect of the invention relates to a method for producing a thin film composition for oral administration according to the first aspect of the invention comprising the steps of:

[0017] a) providing an aqueous solution by dissolving a powder comprising a dead / inactivated microorganism without or with the dried fermentation medium from which it is derived and the medium components therein and an edible acid, b) adding an emulsifier and mixing together the ingredients under stirring and ambient conditions,

[0018] c) adding an aqueous solution comprising a film-forming polymer to the mixture obtained in step b) under stirring and ambient conditions,

[0019] d) adding an aqueous solution comprising a plasticizer to the solution obtained in step c), under stirring and ambient conditions,

[0020] e) applying the solution obtained in step d) onto a flat surface,

[0021] f) casting the thin layer at controlled temperature, and

[0022] g) optionally cutting the dried thin film into desired dimension.

[0023] The third aspect of the invention relates to a thin film composition for oral administration comprising dead / inactivated microorganisms that confer a health benefit on the host, optionally but preferably comprising the dried fermentation medium from which the dead / inactivated microorganisms are derived and the medium components therein obtained or obtainable by the method as disclosed in the second aspect of the invention, including the preferred and the2025P00129WO (34836- WO- PCT)

[0024] 3

[0025] further preferred embodiments. Preferably, the thin film compositions obtained or obtainable according to the third aspect of the invention are those disclosed in the first aspect of the invention, including the preferred and the further preferred embodiments.

[0026] The fourth aspect of the invention relates to a non-medical use of the thin film composition as defined in the first or the third aspect of the invention.

[0027] BRIEF DESCRIPTION OF THE FIGURES

[0028] The invention will be described in further detail hereinafter with reference to the accompanying Figure 1 and 2, in which different embodiments of the thin film composition according to the present application are shown after a storage time of 2 weeks. Pictures were taken with a Canon EOS R5 and Canon EF 24-70mm (Canon, Tokio, Japan) in combination with the AlphaShot 360 (Orbitvu GmbH, Berlin, Germany) and a binocular SMZ171 -BLED, bino, 7,5X-50Xwith Moticam 1080 (MOTICEUROPE, S.L.U., Barcelona, Spain).

[0029] DETAILED DESCRIPTION OF THE INVENTION

[0030] Herein, the following terms have the following meanings:

[0031] “About” or “around” means + / - 5 %.

[0032] “Billion” is one thousand million, that is 109(ten to the ninth power).

[0033] “Dead / inactivated microorganisms” or “inactivated cells from the Lactobacillaceae family” preferably means inanimate cells of a microorganisms or inanimate Lactobacillaceae cells that has been made deliberately lifeless (dead or killed), therefore is not able to colonize under appropriate conditions, for example in the host’s gut. The degree of inactivation is at least 98 %, preferably at least 99 %, more preferably at least 99.5 %, even more preferably substantially all the cells of the microorganism are dead or killed, advantageously the entire population of the microorganism is dead or killed.

[0034] “Free from lactose” in the context of the present application means that no lactose is used during the production process, either in fermentation or in the drying step, and accordingly no lactose can be detected either in the fermentation broth, or in the concentrated broth before or after heat treatment, or in the dried product (powder composition) as disclosed (limit of detection: 50 mg / kg).

[0035] “Free from titanium dioxide” means that the thin film composition for oral administration does not contain titanium dioxide.

[0036] “Loss on drying” (LOD) refers to the loss of weight expressed as a percentage resulting from water loss. In the context of the present application, LOD is determined by drying a sample at2025P00129WO (34836- WO- PCT)

[0037] 4

[0038] 105 °C until a constant weigh is reached. The measurement was stopped when there was no weight reduction of 1 mg within 140 s.

[0039] “Maltodextrin” is an oligosaccharide consisting of 3-20 D-glucose units that are connected to each other mostly by a(1^4) glycosidic bonds (but can have some a(1^6) branches). It is made by partial hydrolysis from corn, rice, potato starch or wheat.

[0040] “Non-therapeutical use” or “non-medical use” means - as opposed to the purpose of therapy which is to restore the organism from a pathological to its original condition, or to prevent pathology in the first place - an improvement of performance of the organism in a normal state. Therefore, the purpose of the non-therapeutical use is to enhance performance and perception of well-being in a healthy state of a mammal / individual or at least in a mammal / individual that is not likely to develop a pathological state.

[0041] “Nutraceutical composition” refers to a formulation that combines nutrients and / or bioactive compounds, designed to provide health benefits beyond basic nutrition. These compositions can be in the form of dietary supplements, functional foods, or beverages that aim to improve overall well-being.

[0042] “Substantially free” means less than 1 wt%.

[0043] “Thin film for oral administration” means a delivery system of a drug or a nutritionally useful ingredient (active ingredient) designed to dissolve quickly upon contact with saliva, facilitating the efficient absorption of medication through the oral mucosa. Thin film is typically composed of a polymer matrix that encapsulates the active ingredients, which are released as the film disintegrates. It is typically designed to be small, flat, and flexible sheets that can easily dissolve in the mouth. Its shape is usually rectangular or square, although it can also be circular or oval depending on the intended use and consumer preference. The thin film is generally small to ensure ease of administration and rapid dissolution. It typically ranges from about 1 to 5 centimetres in length and width, and are very thin, often between 50 to 300 micrometres in thickness. These dimensions make the thin film discreet and convenient to use, allowing them to fit comfortably in the mouth without causing discomfort or obstruction. The thin and flexible nature of the films ensures that they can adhere to the oral mucosa and dissolve quickly, releasing the active ingredients efficiently.

[0044] The present inventors surprisingly found that postbiotic powder preparations, for example preparation of inanimate cells from the Lactobacillaceae family with or without, but preferably with their dried fermentation broth, is suitable for making orally applicable thin film compositions. Therefore, the first aspect of the inventions relates to a thin film composition for oral administration comprising dead / inactivated microorganisms that confer a health benefit on the2025P00129WO (34836- WO- PCT)

[0045] 5

[0046] host. In this regard, the present invention is considered to be a thin film composition for oral administration comprising a postbiotic. Advantageously, the thin film composition also comprises the dried fermentation medium from which the dead / inactivated microorganisms are derived and the medium components therein. Preferably, thin film composition comprises a composition containing the dead / inactivated microorganism with or without its dried fermentation medium, which is present in 30-50 wt% based on the total weight of the orally applicable thin film composition.

[0047] In a preferred embodiment, the thin film composition according to the first aspect of the invention does not contain (or is free from) titanium dioxide. Titanium dioxide (TiO2), also known as E171 when used as a food additive, is preferably not used in compositions intended for human consumption due to unresolved safety concerns, particularly related to genotoxicity, nanoparticle behaviour, and regulatory risk.

[0048] Preferably, the dead / inactivated microorganisms are lactic acid bacteria, more preferably cells from the Lactobacillaceae family.

[0049] More preferably, the dead / inactivated Lactobacillaceae cells belong to the genus Limosilactobacillus, for example Lm. fermentum or Lm. reuteri, and / or to the genus Lactobacillus, for example L. acidophilus, L. delbrueckii, L. delbrueckii subsp. bulgaricus or L. johnsonii, and / or the genus Lactiplantibacillus, for example L. plantarum, and / or to the genus Lacticaseibacillus, for example L. rhamnosus or L. casei, and / or to the genus Levilactobacillus, for example L. brevis.

[0050] In one embodiment, the strain in the Lactobacillaceae family is not considered to be a probiotic. In a more preferred embodiment, the Limosilactobacillus is Limosilactobacillus fermentum as deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) with the reference code I-2998. In other preferred embodiment, the Lactobacillus is Lactobacillus delbrueckii as deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) with the reference code 1-4831.

[0051] In a particularly preferred embodiment, the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, more preferably the strains of in the Limosilactobacillus fermentum and Lactobacillus delbrueckii species are not considered to be probiotics. The ratio of Limosilactobacillus fermentum to Lactobacillus delbrueckii by weight or cell count may be any suitable ratio from about 999:1 to about 9:1, e.g. about 99:1 to 9:1, including 50:1, 25:1, 19:1, particularly about 9:1-50:1, more preferably about 19:1. In an advantageous embodiment, the strain in Lactobacillaceae family is Lactobacillus LB consisting of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by2025P00129WO (34836- WO- PCT)

[0052] 6

[0053] intact cell count). The Lactobacillus LB may conveniently be isolated from human faeces.

[0054] Lactobacillus LB in fermented culture medium (together with components of the culture medium fermentation including peptides, amino acids carbohydrates carbon and minerals) is deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) with the reference code MA 65 / 4E.

[0055] In the context of the first aspect of the invention, the composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which it is derived and the medium components therein, including the preferred and further preferred embodiments disclosed above, is prepared by concentration of the fermentation broth of said microorganism followed by inactivation and drying the inactivated / dead cells together with the fermented culture medium to a powder (that is removing water from the medium). As a result, the preparation of the inactivated cells contains substances other than the intact cells, for example cell components (pili, cell wall components, etc.), fermentation additives like carbon and / or energy source used in the fermentation, microbial metabolites and / or end products like amino acids, peptides. The drying method comprises spray-drying, lyophilization, fluid bed drying or other appropriate process. In a particular embodiment, a carbohydrate compound, e.g. lactose, maltodextrin or cellobiose, may be added to the concentrated fermentation medium prior to drying. In another aspect, a carbohydrate compound, e.g. lactose, maltodextrin or cellobiose, may be added in the course of drying as part of the formulation step to make a dried powder of the dead / inactivated cells with or in the dried fermentation medium from which they are derived and the medium components therein. Preferably, the drying method is fluid bed drying.

[0056] In a preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein comprises lactose, preferably in 50-85 wt% based on the total weight of the powder, more preferably in 65-85 wt%, even more preferably in 70-80 wt% or 75-82 wt%, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram. In a preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein comprises lactose, preferably in 15-23 wt% based on the total weight of the powder, and comprises maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, preferably wherein the lactose and maltodextrin together are present in 50-85 wt% based on the total weight of the powder, even2025P00129WO (34836- WO- PCT)

[0057] 7

[0058] more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0059] In a preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein comprises lactose, preferably in 15-23 wt% based on the total weight of the powder, and comprises cellobiose, preferably wherein the lactose and cellobiose together are present in 50-85 wt% based on the total weight of the powder, even more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0060] In a preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein comprises lactose, preferably in 15-23 wt% based on the total weight of the powder, and comprises cellobiose and maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, preferably the lactose, cellobiose and maltodextrin together being present in 50-85 wt% based on the total weight of the powder, even more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0061] In another preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein is substantially free from lactose, preferably free from lactose, comprises maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, more preferably the maltodextrin being present in 65-85 wt% based on the total weight of the powder, even more preferably 70-80 wt% or 75-82 wt%, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count).2025P00129WO (34836- WO- PCT)

[0062] 8

[0063] This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0064] In another preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein is substantially free from lactose, preferably free from lactose, comprises cellobiose in 65-87 wt% based on the total weight of the powder, preferably in 75-85 wt%, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, and further preferably wherein the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0065] In another preferred realization, the powder composition of the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein is substantially free from lactose, preferably free from lactose, comprises cellobiose and maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, the cellobiose and maltodextrin being present preferably in 65-85 wt% based on the total weight of the powder, even more preferably 70-80 wt% or 75-82 wt%, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, and wherein further preferably the Lactobacillaceae cells comprise or consist of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, preferably in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count). This powder composition comprises 30-90, preferably 50-80 or 60-80 billion cell bodies per gram.

[0066] The thin film according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above, is preferably characterized in that it comprises at least one film-forming polymer. The film-forming polymer is essential component in the thin films as it provides the structural matrix and ensures the film's integrity, flexibility and rapid dissolution in the mouth. Preferably, the at least one film-forming polymer is selected from the group consisting of starch and starch derivatives, dextrans, cellulose derivatives such as carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropylethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose, polyacrylic acids, polyacrylates, polyvinyl pyrrolidones, polyvinyl alcohols, polyvinyl pyrrol idone / polyvinyl acetate copolymers, polyethylene oxide polymers, polyacrylamides, polyvinyl alcohol / polyethylene glycol copolymers, gelatine, collagen, alginates, pectin, pullulan,2025P00129WO (34836- WO- PCT)

[0067] 9

[0068] tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar, agarose, carrageenan, gellan, natural gums like guar gum or locust bean gum and mixtures thereof. Further preferably, the starch or starch derivative comprises hydroxypropyl starch, more preferably hydroxypropyl pea starch.

[0069] Also preferably, the film forming polymers makes up 25-55 wt%, more preferably 28-48 wt% of the thin film composition.

[0070] Accordingly, a preferred embodiment of the first aspect relates to a thin film composition for oral administration comprising:

[0071] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, and a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0072] wherein, preferably, the microorganism in component A is a lactic acid bacterium, even more preferably belongs to the Lactobacillaceae family, further more preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0073] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt% of the thin film composition.

[0074] Furthermore, the thin film according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above, is characterized in that it comprises a plasticizer. Plasticizers enhance the flexibility and pliability of the film, preventing it from becoming brittle or breakable. Suitable plasticizer includes, for example, glycerol, propylene glycol, polyethylene glycol (PEG), sucrose, maltodextrin, sugar alcohols, preferably glycerol. The plasticizer, preferably, makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt% of the thin film composition.

[0075] Accordingly, a preferred embodiment of the first aspect is a thin film composition for oral administration comprising:

[0076] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium2025P00129WO (34836- WO- PCT)

[0077] 10

[0078] components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch, and

[0079] a plasticizer, preferably glycerol,

[0080] wherein preferably the microorganism is a lactic acid bacterium, more preferably belongs to the Lactobacillaceae family, further preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0081] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt% and the plasticizer makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt% of the thin film composition.

[0082] In addition, the thin film according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above, is further characterized in that it comprises an emulsifier (also called surfactant). The emulsifier improves the wetting and spreading properties of the film, aiding in the uniform distribution of the postbiotic. Examples of emulsifiers are polysorbates derived from sorbitol and fatty acids (e.g. Polysorbate 80), sodium lauryl sulfate and lecithin in natural, synthetic or semi-synthetic form, preferably natural lecithin. The emulsifier, preferably, makes up 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt% of the thin film composition.

[0083] Accordingly, another preferred embodiment of the first aspect is a thin film composition for oral administration comprising:

[0084] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0085] a plasticizer, preferably glycerol, and

[0086] an emulsifier, preferably lecithin,2025P00129WO (34836- WO- PCT)

[0087] 11

[0088] wherein preferably the microorganism is a lactic acid bacterium, more preferably belongs to the Lactobacillaceae family, further preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0089] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt%, the plasticizer makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt%, and the emulsifier makes up the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt% of the thin film composition.

[0090] Furthermore, the thin film according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above, is further characterized in that it comprises an edible acid. The edible acid can be an inorganic acid, for example phosphoric acid, and / or an organic acid, for example ascorbic acid, malic acid, citric acid, tartaric acid, fumaric acid, acetic acid or lactic acid. The edible acid is preferably an organic acid, more preferably citric acid, ascorbic acid or malic acid. The function of the acid in the thin film composition according to the present invention is to stimulate the salivary glands and thereby trigger salivation contributing to the better disintegration of the film in the mouth in one hand, and to enhance the sensory experience on the other hand. The acid can be present in up to 20 wt% in the thin film composition.

[0091] Accordingly, another preferred embodiment of the first aspect is a thin film composition for oral administration comprising:

[0092] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0093] a plasticizer, preferably glycerol,

[0094] an emulsifier, preferably lecithin, and

[0095] an edible acid,

[0096] wherein preferably the microorganism is a lactic acid bacterium, more preferably belongs to the Lactobacillaceae family, further preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly2025P00129WO (34836- WO- PCT)

[0097] 12

[0098] Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0099] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt%, the plasticizer makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt%, and the emulsifier makes up the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt%, and the edible acid makes up 0.1-20 wt% of the thin film composition.

[0100] Advantageously, if the edible acid is ascorbic acid or citric acid, it is present in the thin film composition in more than 5 wt%, preferably in around 9-16 wt%; if the edible acid is malic acid, it is present in the thin film composition up to 0.5 wt%.

[0101] The thin film composition according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above is also characterized in that it contains water in 5-15 wt%. The water in the thin film composition according to the present invention is determined in loss on drying experiment, that is drying the thin film sample at 105 °C until a constant weigh is reached. The measurement is stopped when less then 1 mg of weight reduction is reached within 140 s.

[0102] Accordingly, another preferred embodiment of the first aspect is a thin film composition for oral administration comprising:

[0103] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0104] a plasticizer, preferably glycerol,

[0105] an emulsifier, preferably lecithin,

[0106] an edible acid, and

[0107] - water,

[0108] wherein preferably the microorganism is a lactic acid bacterium, more preferably belongs to the Lactobacillaceae family, further preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831,2025P00129WO (34836- WO- PCT)

[0109] 13

[0110] advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0111] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt%, the plasticizer makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt%, and the emulsifier makes up the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt%, the edible acid makes up 0.1-20 wt%, and the water makes up 5-15 wt%, preferably 8-12 wt% of the thin film composition.

[0112] Advantageously, if the edible acid is ascorbic acid or citric acid, it is present in the thin film composition in more than 5 wt%, preferably in around 9-16 wt%; if the edible acid is malic acid, it is present in the thin film composition up to 1 wt%.

[0113] The thin film composition according to the first aspect of the invention, including the preferred and further preferred embodiments disclosed above can contain additional optional components.

[0114] For example, the thin film can comprise optionally a sweetener. The sweetener improves the taste of the film, making it more palatable for consumers. The sweetener can be a usual sugar such as sucrose, glucose, fructose, high fructose corn syrup or mixture thereof, which can be present up to 20 wt%. In other embodiments, the sweetener can be artificial or low-calorie sweeteners, especially in thin film composition according to the present invention intended for use for diabetics, such as xylitol, erythritol, sorbitol, mannitol, isomalt, maltitol or any mixture thereof as examples of low-calorie sugar alcohols, which can be present in up to 20 wt% in the thin film composition, or aspartame, sucralose, stevia, monk fruit, saccharin, acesulfame K, neotame, advantame or cyclamate as examples of artificial sweeteners, which can be present in up to 2 wt% in the thin film composition.

[0115] In addition, the thin film can contain optionally a flavouring agent, for example orange, berry, citrus, mint, etc. flavour or a mix of them, that can mask the taste of one or more ingredients of the thin film and enhance the overall flavour of the film. If present, the flavouring agent can be present up to 5 wt% of the thin film composition.

[0116] Additionally, the thin film can optionally comprise a colouring agent to provide visual appearance and help differentiate between different formulations. The optional colouring agent may be present in up to 3 wt% of the thin film.

[0117] Further, the thin film can also contain a stabilizer or preservative as an optional ingredient in up to 2 wt% to contribute to the stability and shelf-life of the film. Typical preservative is e.g. sodium benzoate or potassium sorbate.2025P00129WO (34836- WO- PCT)

[0118] 14

[0119] Accordingly, another preferred embodiment of the first aspect is a thin film composition for oral administration comprising:

[0120] as component A: a composition containing dead / inactivated cells of a microorganism with or in the dried fermentation medium from which they are derived and the medium components therein that confer a health benefit on the host, which is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0121] a plasticizer, preferably glycerol,

[0122] an emulsifier, preferably lecithin,

[0123] an edible acid, and

[0124] - water,

[0125] wherein preferably the microorganism is a lactic acid bacterium, even more preferably belongs to the Lactobacillaceae family, further preferably the Lactobacillaceae cells comprise or consist of two independent species: Limosilactobacillus fermentum and Lactobacillus delbrueckii, particularly Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM I-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count), and / or

[0126] wherein, preferably, the film forming polymer makes up 25-55 wt%, more preferably 28-48 wt%, the plasticizer makes up 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt%, and the emulsifier makes up the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt%, the edible acid makes up 0.1-20 wt%, and the water makes up 5-15 wt%, preferably 8-12 wt% of the thin film composition, and

[0127] optionally comprises a sweetener, preferably sucralose in an amount of up to 2 wt% or sucrose in an amount of up to 20 wt%, and / or

[0128] optionally comprises a flavouring agent, more preferably in an amount of up to 5 % wt%, and / or optionally comprises a colouring agent, more preferably in an amount of up to 3 wt%, and / or optionally comprises a stabilizer or preservative, more preferably in an amount of up to 2 wt%. Advantageously, if the edible acid is ascorbic acid or citric acid, it is present in the thin film composition in more than 5 wt%, preferably in around 9-16 wt%; if the edible acid is malic acid, it is present in the thin film composition up to 1 wt%.2025P00129WO (34836- WO- PCT)

[0129] 15

[0130] In the embodiments disclosed above, component A preferably comprises 30-90 billion cell bodies per gram, preferably 50-80 or 60-80 billion cell bodies per gram.

[0131] Furthermore, the thin film composition according to the present invention can also comprise further active ingredients (next to the postbiotic powder). Preferred active ingredients for the embodiment of the present invention may include vitamins (other than vitamin C), carotenoids, nutritional lipids, minerals, nutraceuticals, amino acids, botanicals, prebiotics, probiotics, fibres or any combination thereof that are useful in human nutrition. Such additional active ingredients may be present in amount of up to 10 wt%, based on the total weight of the thin film composition.

[0132] Especially preferred embodiments of the first aspect of the invention are thin film composition for oral administration comprising:

[0133] a composition containing dead / inactivated cells from the Lactobacillaceae family consisting of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count) with or in the dried fermentation medium from which they are derived and the medium components therein, as component A,

[0134] a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,

[0135] a plasticizer, preferably glycerol,

[0136] an emulsifier, preferably lecithin,

[0137] an edible acid, and

[0138] - water,

[0139] wherein component A comprises 30-90 billion cell bodies per gram, preferably 50-80 or 60-80 billion cell bodies per gram and is present in 30-50 wt%, preferably in 38-45 wt% based on the total weight of the thin film composition, and component A

[0140] is substantially free from lactose, preferably free from lactose, and comprises

[0141] o maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, the maltodextrin preferably being present in 65-85 wt% based on the total weight of component A, even more preferably in 70-80 wt% or 75-82 wt%, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, o cellobiose, preferably in 65-87 wt% based on the total weight of component A, even more preferably 75-85 wt%, and optionally a carbohydrate different from2025P00129WO (34836- WO- PCT)

[0142] 16

[0143] lactose which has been used as energy and / or carbon source in the fermentation previously, or

[0144] o cellobiose and maltodextrin, the maltodextrin being preferably maltodextrin of 8- 20 DE, more preferably 12-20 DE, the cellobiose and maltodextrin being present preferably in 65-85 wt% based on the total weight of component A’, even more preferably 70-80 wt% or 75-82 wt%, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously,

[0145] or

[0146] comprises lactose, preferably

[0147] o in 50-85 wt% based on the total weight of component A, preferably in 65-85 wt%, more preferably in 70-80 wt% or 75-82 wt%, or

[0148] o in 15-23 wt% based on the total weight of component A’ and further comprises ■ maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, wherein the lactose and maltodextrin together are present in 50-85 wt% based on the total weight of component A, even more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, or ■ cellobiose, more preferably wherein the lactose and cellobiose together are present in 50-85 wt% based on the total weight of component A, even more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, or ■ maltodextrin and cellobiose, the maltodextrin being preferably maltodextrin of 8-20 DE, more preferably 12-20 DE, more preferably wherein the lactose, maltodextrin and cellobiose together are present in 50-85 wt% based on the total weight of component A, even more preferably in 65-85 wt%, particularly in 70-80 wt% or 75-82 wt%, wherein the film forming polymer makes up 25-55 wt%, preferably 28-48 wt%, the plasticizer makes up 1-20 wt%, preferably 4-16 wt%, more preferably 8-12 wt%, the emulsifier makes up the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5wt%, the edible acid makes up 0.1-20 wt%, and the water makes up 5-15 wt%, preferably 8-12 wt% of the thin film composition. Advantageously, if the edible acid is ascorbic acid or citric acid, it is present in the thin film composition in more than 5 wt%, preferably in around 9-16 wt%; if the edible acid is malic acid, it is present in the thin film composition up to 1 wt%.2025P00129WO (34836- WO- PCT)

[0149] 17

[0150] The inventors surprisingly discovered that the addition of the postbiotic powder helps to prevent phase separation in the thin film compositions upon storage as evidenced by absence of clustered zones due to material migration or segregation, compared to thin film composition prepared without the addition of postbiotic powder.

[0151] Apart form the advantages mentioned above, the thin film according to the present invention provides additional benefits. One of the benefits is its ease of administration. Postbiotics are usually available as powders; the thin film simply needs to be placed on the tongue or inside the cheek, where it dissolves rapidly. This feature significantly enhances patient compliance, especially among children and elderly individuals who may struggle with conventional oral dosage forms of postbiotics. Additionally, the thin film can provide a faster onset of action compared to traditional oral forms. Furthermore, the thin film is highly portable and discreet, making them convenient for use in various settings, including travel and public places.

[0152] Compared to the powder form of postbiotics, the thin film does not require water for administration, which adds to its convenience and accessibility.

[0153] The second aspect of the present application relates to a method for producing a thin film composition for oral administration comprising a dead / inactivated microorganism that confer a health benefit on the host. The manufacturing process comprises the steps of:

[0154] a) providing an aqueous solution by dissolving a composition, preferably a powder, comprising a dead / inactivated microorganism without or with the dried fermentation medium from which it is derived and the medium components therein and an edible acid,

[0155] b) adding an emulsifier and mixing together the ingredients under stirring and ambient conditions,

[0156] c) adding an aqueous solution comprising a film-forming polymer to the mixture obtained in step b) under stirring and ambient conditions,

[0157] d) adding an aqueous solution comprising a plasticizer to the solution obtained in step c), under stirring and ambient conditions,

[0158] e) applying the solution obtained in step d) onto a flat surface,

[0159] f) casting the thin layer at controlled temperature, and

[0160] g) optionally cutting the dried thin film into desired dimension.

[0161] When mixing the solutions / ingredient together in steps b), c) and d), the stirring is continued until a homogeneous solution is obtained which requires a couple of minutes of stirring (the length of which depends on the speed of stirring). This prevents lump formation and reduced air2025P00129WO (34836- WO- PCT)

[0162] 18

[0163] entrapment which later disturb the film casting by creating holes or cracks in the texture of the final thin film.

[0164] Optional ingredients such as flavouring agent, sweetener, colouring agent, stabilizer and / or additional active ingredients like water soluble vitamins may be added before step c), preferably before step b) .Oil soluble vitamins are usually added with the emulsifier.

[0165] Steps a) to d) are performed so that the solution obtained after step d) has a concentration of about 55-65 wt% in terms of the total dry matter.

[0166] Preferably, the solution obtained after step d) contains the following ingredients:

[0167] the composition containing the dead / inactivated microorganism without or with the dried fermentation medium from which it is derived and the medium components therein in 20- 34 wt%, preferably in 25-30 wt%,

[0168] the film forming polymer in 15-35 wt%, preferably in 17-27 wt%,

[0169] the plasticizer in 0.7-14 wt%, preferably in, 2.5-11 wt%, more preferably in 4-8 wt%, the emulsifier in 0.05-3.5 wt%, preferably in 0.3-2.5 wt%, more preferably in 0.7-1.7 wt%, and

[0170] the edible acid in 0.05-13 wt%, preferably in 3.5-13 wt%, more preferably in 5-10 wt% if the edible acid is ascorbic acid or citric acid, or preferably in 0.05-0.7 wt% if the edible acid is malic acid

[0171] in terms of the total dry matter.

[0172] Furthermore, the solution obtained after step d) may optionally contain the following ingredients:

[0173] a sweetener, preferably sucralose in an amount of up to 1.3 wt% or sucrose in an amount of up to 13 wt%, and / or

[0174] a flavouring agent, preferably in an amount of up to 3.5 % wt%, and / or

[0175] a colouring agent, preferably in an amount of up to 2 wt%, and / or

[0176] a stabilizer or preservative, preferably in an amount of up to 1.5 wt%, and / or

[0177] further active ingredients, preferably vitamins (other than vitamin C), carotenoids, nutritional lipids, minerals, nutraceuticals, amino acids, botanicals, prebiotics, probiotics, fibres or any combination thereof, more preferably in amount of up to 6.5 wt%

[0178] in terms of the total dry matter.

[0179] Step f), preferably, is carried out at a temperature of around 30-80 °C, preferably at around 35-65 °C and at around 20-55 % relative humidity in a suitable equipment, e.g. in a drying oven, for2025P00129WO (34836- WO- PCT)

[0180] 19

[0181] a time until the so-formed thin film has a water content of 5-15 wt%, preferably 8-12 wt% determined by a loss of drying experiment disclosed above. If the thin film comprises heat sensitive ingredient(s), e.g. heat sensitive vitamins, the temperature is preferably set closer the to the lower end of the above ranges.

[0182] The third aspect of the invention relates to a thin film composition for oral administration comprising a composition containing dead / inactivated microorganisms that confer a health benefit on the host, optionally but preferably comprising the dried fermentation medium from which the dead / inactivated microorganisms are derived and the medium components therein obtained or obtainable by the method as disclosed in the second aspect of the invention, including the preferred and the further preferred embodiments. Preferably, the thin film compositions obtained or obtainable according to the third aspect of the invention are those disclosed in the first aspect of the invention, including the preferred and the further preferred embodiments.

[0183] The embodiments of the thin film composition according to the first or the third aspect of the invention that are substantially free from lactose, preferably free from lactose, and contain dead / inactivated cells from the Lactobacillaceae family, preferably those comprising or consisting of Limosilactobacillus fermentum CNCM I-2998 and / or Lactobacillus delbrueckii CNCM 1-4831, advantageously in about a 9:1-50:1, more preferably about 19:1 ratio (by intact cell count) with or in the dried fermentation medium from which they are derived and the medium components therein, as disclosed above, especially offer the benefits of the presently commercialized lactose containing postbiotic powders for those who cannot or don’t consume lactose due to dietary choices or health-related reasons. Furthermore, the composition, preferbaly the powder composition, containing the dead / inactivated cells from the Lactobacillaceae family with or in the dried fermentation medium from which they are derived and the medium components therein, which is substantially free from lactose, preferably free from lactose, and used for making the thin film composition according to the first or the third aspect of the invention, contains higher amounts of useful fermentation metabolites at the same or similar cell count compared to the commercial lactose-containing Humiome® Post LB powder. Therefore, increase of these metabolites in the lactose-free postbiotic powder and thereby in the thin film composition according to the first or the third aspect of the invention comprising the lactose-free postbiotic powder is deemed positive and beneficial.

[0184] The fourth aspect of the invention relates to a non-medical use of the thin film composition as defined in the first or the third aspect of the invention, including the preferred and more preferred embodiments, for enhancing performance and perception of well-being in a healthy state of a mammal / individual or in a mammal / individual that is not likely to develop a pathological state. The mammal is preferably human. One embodiment of use for enhancing2025P00129WO (34836- WO- PCT)

[0185] 20

[0186] performance and perception of well-being is dietary supplementation. In this regard, the thin film composition as defined in the first or the third aspect of the invention can be used as a nutraceutical composition.

[0187] EXAMPLES

[0188] Example 1

[0189] Ascorbic acid (2.5 g) and a dried postbiotic powder of heat-deactivated Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 cells (ratio: 19:1) together with their dried fermentation medium (containing 82 wt% lactose and 62 billion intact cells per gram, 10 g) were dissolved in water (10 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 2.5 g) and sunflower lecithin dispersion (12.3 wt%, 2.85 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.05 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 7.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (2.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.

[0190] Concentration in the thin film solution in wt% Ingredients

[0191] Formulation with postbiotic Formulation without postbiotic LYCAGEL 20.04 27.35

[0192] Glycerol 5.34 7.29

[0193] Lecithin 0.94 1.28

[0194] Blood Orange Flavour 0.13 0.18

[0195] Sucralose 0.05 0.07

[0196] Ascorbic acid 6.68 9.12

[0197] Postbiotic 26.72 -

[0198]

[0199] Water 40.09 54.70

[0200] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 5.5 wt%.

[0201] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was about 6.0 wt%.

[0202] Directly after production, the surface of both films looked continuous and homogeneous, without any defect. After two weeks storage, the surface of the oral dispersible film containing2025P00129WO (34836- WO- PCT)

[0203] 21

[0204] postbiotics remained homogeneous, showing no phase separation. In contrast, the surface of the film without postbiotics became uneven, exhibiting noticeable roughness, which indicates phase separation or blooming (Fig. 1).

[0205] Example 2

[0206] Malic acid (0.15 g) and a dried postbiotic powder of heat-deactivated Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 cells (ratio: 19:1) together with their dried fermentation medium (containing 82 wt% lactose and 62 billion intact cells per gram, 30 g) were dissolved in water (30 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 7.56 g) and sunflower lecithin dispersion (12.3 wt%, 8.55 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.15 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 22.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (6.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.

[0207] Concentration in the thin film solution in wt% Ingredients

[0208] Formulation with postbiotic Formulation without postbiotic LYCAGEL 21.45 30.04

[0209] Glycerol 5.72 8.01

[0210] Lecithin 1.00 1.40

[0211] Blood Orange Flavour 0.14 0.20

[0212] Sucralose 0.06 0.08

[0213] Malic acid 0.14 0.20

[0214] Postbiotic 28.60 -

[0215]

[0216] Water 42.89 60.07

[0217] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 10.3 wt%.

[0218] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was 11.5 wt%.

[0219] Directly after production, the surface of the film containing postbiotics looked continuous and homogeneous, without any defect, whereas the surface of the film without postbiotics, although being quite homogeneous, presented some asperities but in a marginal way. After two weeks2025P00129WO (34836- WO- PCT)

[0220] 22

[0221] storage, the surface of the oral dispersible film containing postbiotics remained homogeneous, without phase separation. In contrast, the roughness of the film without postbiotics has become much more pronounced, with the creation of holes of different size (Fig 1).

[0222] Example 3

[0223] Ascorbic acid (7.5 g) and a powder of an algae-based postbiotic (BetaVia™, Kemin Industries Inc, 7.5 g) were dissolved in water (30 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 7.56 g) and sunflower lecithin dispersion (12.3 wt%, 8.55 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.15 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 22.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (6.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.

[0224] Concentration in the thin film solution in wt% Ingredients

[0225] Formulation with postbiotic Formulation without postbiotic LYCAGEL 25.07 27.35

[0226] Glycerol 6.68 7.29

[0227] Lecithin 1.17 1.28

[0228] Blood Orange Flavour 0.17 0.18

[0229] Sucralose 0.07 0.07

[0230] Ascorbic acid 8.36 9.12

[0231] Postbiotic 8.36 -

[0232]

[0233] Water 50.13 54.70

[0234] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 8.8 wt%.

[0235] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was 8.8 wt%.

[0236] Directly after production, the surface of the two films were very similar, continuous and homogeneous, without any defects. After 2 weeks storage, the surface of the film with postbiotics still looked continuous, whereas the surface of the film without postbiotics looked different: visible whitish spots and cloudy irregularities are clearly identified, suggesting phase separation or surface blooming (Fig 1).2025P00129WO (34836- WO- PCT)

[0237] 23

[0238] Example 4

[0239] Ascorbic acid (7.5 g) and a dried postbiotic powder of heat-deactivated Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 cells (ratio: 19:1) together with their dried fermentation medium (containing 82 wt% lactose and 62 billion intact cells per gram, 30 g), ampli-D® (3 g), vitamin B2 (0.45 g) and vitamin B12 (as 1 % formula, 0.15 g) were dissolved in water (30 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 7.56 g) and sunflower lecithin dispersion (12.3 wt%, 8.55 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.15 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 22.5 g) was added to the previous solution and stirred for 5 min under ambient conditions.

[0240] Glycerol (6.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.

[0241] Concentration in the thin film solution in %

[0242] Ingredient

[0243] Formulation with postbiotic Formulation without postbiotic LYCAGEL 19.37 26.67

[0244] Glycerol 5.17 7.11

[0245] Lecithin 0.90 1.24

[0246] Blood Orange Flavour 0.13 0.18

[0247] Sucralose 0.05 0.07

[0248] Ascorbic acid 6.46 8.89

[0249] ampli-D®* 2.58 1.78

[0250] Vitamin B2 0.65 0.53

[0251] Vitamin B12 1% 0.129 0.178

[0252] Postbiotic 25.826 -

[0253]

[0254] Water 38.740 53.343

[0255] * ampli-D® is an advanced and potent form of vitamin D by dsm-firmenich

[0256] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 8.7 wt%.

[0257] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was 12.1 wt. %.

[0258] Directly after production, the surface of the film containing postbiotics looked continuous and homogeneous, without any defect, whereas the surface of the film without postbiotics, although2025P00129WO (34836- WO- PCT)

[0259] 24

[0260] being quite homogeneous, presented some minor defects but in a marginal way. After storage, the surface of the film containing postbiotics looked a bit rougher. In contrast, the surface of the film without postbiotics exhibited an irregular surface, with an extremely pronounced cloudy appearance and high roughness, suggesting phase separation or surface blooming (Fig 1). Example 5

[0261] Ascorbic acid (7.5 g) and a dried postbiotic powder of heat-deactivated Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 cells (ratio: 19:1) together with their dried fermentation medium (containing 82 wt% lactose and 62 billion intact cells per gram, 30 g) and ampli-D® (3 g) were dissolved in water (30 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 7.56 g) and sunflower lecithin dispersion (12.3 wt%, 8.55 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.15 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 22.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (6.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.

[0262] Concentration in the thin film solution in %

[0263] Ingredient

[0264] Formulation with postbiotic Formulation without postbiotic LYCAGEL 19.52 26.39

[0265] Glycerol 5.21 7.04

[0266] Lecithin 0.91 1.23

[0267] Blood Orange Flavour 0.13 0.18

[0268] Sucralose 0.05 0.07

[0269] Ascorbic acid 6.51 8.80

[0270] ampli-D®* 2.60 3.52

[0271] Postbiotic 26.03 -

[0272]

[0273] Water 39.042 52.780

[0274] * ampli-D® is an advanced and potent form of vitamin D by dsm-firmenich

[0275] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 8.0 wt%.

[0276] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was 8.6 wt%.2025P00129WO (34836- WO- PCT)

[0277] 25

[0278] Directly after production, the surface of the two films were very similar, continuous and homogeneous, without any defects. After 2 weeks storage, the surface of the film with postbiotics still looked homogeneous with no phase separation. In contrast, the surface of the film without postbiotics exhibited a clear phase separation with creation of visible whitish spots forming a large area, suggesting phase separation or surface blooming (Fig 1).

[0279] Example 6

[0280] Preparation of the lactose-free postbiotic powder

[0281] A culture medium comprising yeast extract , sodium acetate dipotassium phosphate and glucose (30 g / l) was inoculated with Lactobacillus LB {Lm. fermentum and L. delbrueckii in about a 9:1 ratio, deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) with the reference code MA 65 / 4E) and fermented at 37 °C for 16 hours to reach a cell count of 1-1.5 billion / ml. Residual glucose was 13 g / l. The fermentation broth was concentrated under vacuum to cca.1 / 5thof the original volume, to which a filtered biomass from a parallel Lactobacillus LB fermentation was added to set the total solids to be 21 w / v%. The pH of the so obtained suspension was set to 5 with calcium carbonate and subjected to thermal treatment (110 °C, 1 h) to inactivate the cells.

[0282] The concentrated and heat-treated suspension obtained above was dried in a fluid bed dryer using maltodextrin of DE 12 at 50 °C to produce a free flowing creamy yellow powder, wherein 3.5 kg of maltodextrin was used for each kg of the total solids in the suspension. Results: maltodextrin: 74 wt%, glucose: 4.0 wt%, cell count: 70 billion / g.

[0283] Example 7

[0284] Ascorbic acid (2.5 g) and a dried postbiotic powder according to Example 6 (10 g) were dissolved in water (10 g) at room temperature for 5 minutes under stirring. Sucralose solution (0.79 % wt%, 2.5 g) and sunflower lecithin dispersion (12.3 wt%, 2.85 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.05 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 7.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (2.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.2025P00129WO (34836- WO- PCT)

[0285] 26

[0286] Concentration in the thin film solution in wt% Ingredients

[0287] Formulation with postbiotic Formulation without postbiotic LYCAGEL 20.04 27.35

[0288] Glycerol 5.34 7.29

[0289] Lecithin 0.94 1.28

[0290] Blood Orange Flavour 0.13 0.18

[0291] Sucralose 0.05 0.07

[0292] Ascorbic acid 6.68 9.12

[0293] Postbiotic 26.72 -

[0294]

[0295] Water 40.09 54.70

[0296] The thin film was generated by spreading the solution with the thin film spreading device (CAMAG) at a gap of 500 pm on a steel plate (SLIS304). To allow an easier peel off from the steel plate, CAPOL 3073 A was spread on the steel plate before. The film casting was carried out at 60 °C and 50 % relative humidity in a drying oven HPP260eco (Memmert GmbH + Co. KG Schwabach, Germany) for 50 minutes. Finally, the thin film was peeled off from the steel plate with the help of a steel scraper. The measured LOD of the film was 3.9 wt%.

[0297] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOD of the film was 6.0 wt%.

[0298] Directly after production, the surface of both films looked continuous and homogeneous, without any defect. After two weeks storage, the surface of the oral dispersible film containing postbiotics remained homogeneous, showing no phase separation. In contrast, the surface of the film without postbiotics became uneven, exhibiting noticeable roughness, which indicates phase separation or blooming (Fig 1).

[0299] Example 8

[0300] Ascorbic acid (7.5 g) and a dried postbiotic powder of heat-deactivated Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 cells (ratio: 19:1) together with their dried fermentation medium (containing 82 wt% lactose and 62 billion intact cells per gram, 30 g) at room temperature for 5 minutes under stirring. Dextrose or sucrose solution (9.09 wt%, 8.25 g) and sunflower lecithin dispersion (12.3 wt%, 8.55 g) were added to this solution under gentle stirring for 5 minutes at ambient conditions. Then flavour (blood orange, 0.15 g) was added under stirring. Afterwards, hydroxypropyl pea starch (LYCAGEL® VS 720, 22.5 g) was added to the previous solution and stirred for 5 min under ambient conditions. Glycerol (6.0 g) was added and stirred for 1 min under ambient conditions. The final concentration of the ingredients in the solution is given in the table below.2025P00129WO (34836- WO- PCT)

[0301] 27

[0302] Concentration in the thin film solution in wt% Ingredients

[0303] Formulation with postbiotic Formulation without postbiotic LYCAGEL 19.92 27.12

[0304] Glycerol 5.31 7.23

[0305] Lecithin 0.93 1.27

[0306] Blood Orange Flavour 0.13 0.18

[0307] Dextrose or sucrose 0.66 0.90

[0308] Ascorbic acid 6.64 9.04

[0309] Postbiotic 26.56 -

[0310]

[0311] Water 39.84 54.25

[0312] The thin film was generated as described in Example 7. The LOP measured of the film was 8.45 wt% in both cases.

[0313] The same procedure was followed with the difference that the postbiotic powder was not added. The measured LOP of the film was 9.84 wt% in both cases.

[0314] Pirectly after production, the surface of the films looked continuous and homogeneous, without any defect. After two weeks storage, the surface of the oral dispersible films containing postbiotics remained homogeneous, showing no phase separation. In contrast, the surface of the films without postbiotics became uneven, exhibiting noticeable roughness, which indicates phase separation or blooming (Fig 2).

[0315] Example 9

[0316] Metabolites produced during fermentation and present in the powders were measured in three batches of a lactose-free postbiotic composition and compared to those in three batches of reference Humiome® Post LB containing lactose.

[0317] lactose-free postbiotic fluid bed dried Humiome® Post LB powders powders lactose (wt%) - 68-70 glucose (wt%) 3.4-4.4 - maltodextrin (wt%) 77-78 - lactic acid bacteria (billion

[0318] 70-79 64-75

[0319]

[0320] cells / g)

[0321] Lactic acid was analysed by liquid chromatography mass spectrometry (LC-MS) using a modified version of the methods disclosed in the prior art (Shafaei et al. Anal. Bioanal. Chem.

[0322] 413, 6333 (2021); Liebisch et al. Biomolecules 9, 121 (2019); Han et al. Anal. Chim. Acta 854, 86 (2015)) using a Thermo Scientific Accela UHPLC system coupled to a Q Exactive Orbitrap mass spectrometer. Pure lactic acid was used as calibration control and internal standard.

[0323] Postbiotic samples were extracted in a 50% methanol, the supernatant containing lactic acid:2025P00129WO (34836- WO- PCT)

[0324] 28

[0325] was derivatized with13Ce-labeled 3-nitrophenylhydrazine (3NPH) using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) in a solvent mixture of water and acetonitrile containing pyrimidine. Derivatized samples and calibration standard were diluted in water and analysed by LC-MS on a Thermo Scientific Accela LIHPLC system using a C18 column coupled to a Q Exactive Orbitrap mass spectrometer (MS) with atmospheric pressure chemical ionization (APCI).

[0326] GABA (y-aminobutyric acid) was analysed by LC-MS without prior derivatization using adaptation of known methods (Wu et al. Food Funct. 10, 6484 (2019); Jia et al. Molecules 25, 1862 (2020); Hefni et al. Anal. Bioanal. Chem. 413, 5349 (2021); Lamy et al. Taianta 224, 121881 (2021)). Postbiotic samples were extracted as described above and the internal standards in acetonitrile were added to the supernatants. Analysis was performed with a Thermo Vanquish UHPLC system equipped with a Waters Aquity UPLC BEH HILIC column with a gradient elution of ammonium formate and formic acid in water (eluent A) and acetonitrile (eluent B). Thereafter, fractions were analysed by positive electrospray ionization mass spectrometry on a Thermo Stellar mass spectrometer.

[0327] The comparative analysis showed that the lactose-free postbiotic powders contained higher concentration of useful fermentation metabolites at the same or similar cell count compared to the commercial lactose-containing Humiome® Post LB. Notably, the following average increases were measured: lactic acid 28 %; GABA 298 %. Lactic acid is a beneficial compound produced by certain gut bacteria, especially Lactobacillus species, during the fermentation of carbohydrates. Higher levels of lactic acid in the gut help maintain a healthy pH balance, inhibit the growth of harmful microbes, and support overall gut barrier integrity and immune function. GABA is a key inhibitory neurotransmitter that helps calm brain activity and is also produced in the gut, where it influences the gut-brain axis. Higher levels of GABA are generally associated with reduced anxiety and depression symptoms, and certain gut microbes that boost GABA production may support mental well-being by positively affecting mood-regulating neural pathways. Therefore, increase of these metabolites in the lactose-free postbiotic powder and thereby in the thin film composition according to the present invention comprising the lactose-free postbiotic powder is deemed positive and beneficial.

Claims

2025P00129WO (34836- WO- PCT)29CLAIMS1. A thin film composition for oral administration comprising a composition containing dead / inactivated microorganisms that confer a health benefit on the host, preferably in 30- 50 wt% based on the total weight of the thin film composition.

2. The thin film composition according to claim 1, which is free from titanium dioxide.

3. The thin film composition according to claim 1 or 2, wherein the inactivated microorganism is a lactic acid bacterium, preferably with or in the dried fermentation medium from which it is derived and the medium components therein.

4. The thin film composition according to any of the claims 1 to 3, wherein the lactic acid bacterium belongs to the genus Limosilactobacillus and / or to the genus Lactobacillus, preferably a species in the Limosilactobacillus genus is Limosilactobacillus fermentum and / or a species in the Lactobacillus genus is Lactobacillus delbrueckii.

5. The thin film composition according to any of the preceding claims, wherein the lactic acid bacterium comprises or consists of Limosilactobacillus fermentum and Lactobacillus delbrueckii, preferably the Limosilactobacillus fermentum being Limosilactobacillus fermentum CNCM I-2998 and the Lactobacillus delbrueckii being Lactobacillus delbrueckii CNCM 1-4831.

6. The thin film composition according to claim 5, wherein the Limosilactobacillus fermentum and Lactobacillus delbrueckii are present in about a 9:1-50:1, preferably about 19:1 ratio by intact cell count.

7. The thin film composition according to any of the preceding claims, further comprising a film forming polymer, a plasticizer, an emulsifier, an edible acid and water.

8. The thin film composition according to claim 7, wherein thethe film forming polymer is in 25-55 wt%, more preferably 28-48 wt%, the plasticizer is in 1-20 wt%, more preferably 4-16 wt%, even more preferably 8-12 wt%,the emulsifier is in the 0.1-5 wt%, preferably 0.5-3.5 wt%, more preferably 1-2.5 wt%, andthe water is in 5-15 wt%, preferably 8-12 wt%based on the total weight of the thin film composition.

9. The thin film composition according to claim 7 or 8, wherein2025P00129WO (34836- WO- PCT)30- the film forming polymer is starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,- the plasticizer is glycerol,- the emulsifier is lecithin, and- the edible acid is ascorbic acid, citric acid or malic acid.

10. The thin film composition according to any of the preceding claims, comprising:a composition containing dead / inactivated cells from the Lactobacillaceae family consisting of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 with or in the dried fermentation medium from which they are derived and the medium components therein as component A’,a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,a plasticizer, preferably glycerol,an emulsifier, preferably lecithin,an edible acid, and- water,wherein component A comprises 30-90 billion cell bodies per gram and is present in 30-50 wt% based on the total weight of the thin film composition, and component A comprises lactose, preferably in 50-85 wt% based on the total weight of component A,wherein the film forming polymer makes up 25-55 wt%, the plasticizer makes up 1-20 wt%, the emulsifier makes up the 0.1-5 wt%, the edible acid makes up 0.1-20 wt%, and the water makes up 5-15 wt% of the thin film composition.

11. The thin film composition according to any of the claims 1 to 9, which is substantially free from lactose, preferably free from lactose.

12. The thin film composition according to claim 11, comprisinga composition containing dead / inactivated cells from the Lactobacillaceae family consisting of Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii CNCM 1-4831 with or in the dried fermentation medium from which they are derived and the medium components therein as component A,a film forming polymer comprising starch or a starch derivative, preferably hydroxypropyl starch, more preferably hydroxypropyl pea starch,2025P00129WO (34836- WO- PCT)31a plasticizer, preferably glycerol,an emulsifier, preferably lecithin,an edible acid, and- water,wherein component A’ comprises 30-90 billion cell bodies per gram and is present in 30-50 wt% based on the total weight of the thin film composition, and component A comprises maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, the maltodextrin preferably being present in 65-85 wt% based on the total weight of component A, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, cellobiose, preferably in 65-87 wt% based on the total weight of component A, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously, orcellobiose and maltodextrin, the maltodextrin being preferably maltodextrin of 8-20 DE, the cellobiose and maltodextrin being present preferably in 65-85 wt% based on the total weight of component A, and optionally a carbohydrate different from lactose which has been used as energy and / or carbon source in the fermentation previously,wherein the film forming polymer makes up 25-55 wt%, the plasticizer makes up 1-20 wt%, the emulsifier makes up the 0.1-5 wt%, the edible acid makes up 0.1-20 wt%, and the water makes up 5-15 wt% of the thin film composition.

13. A method for producing a thin film composition according any of the precedent claims, the method comprising the steps of:a) providing an aqueous solution by dissolving a powder comprising a dead / inactivated microorganism without or with the dried fermentation medium from which it is derived and the medium components therein and an edible acid, b) adding an emulsifier and mixing together the ingredients under stirring and ambient conditions,c) adding an aqueous solution comprising a film-forming polymer to the mixture obtained in step b) under stirring and ambient conditions,d) adding an aqueous solution comprising a plasticizer to the solution obtained in step c), under stirring and ambient conditions,2025P00129WO (34836- WO- PCT)32e) applying the solution obtained in step d) onto a flat surface,f) casting the thin layer at controlled temperature, andg) optionally cutting the dried thin film into desired dimension.

14. A thin film composition for oral administration obtained or obtainable by the method comprising the steps as defined in claim 14.

15. A non-medical use of the thin film composition as defined in any of the claims 1 to 12 and 14 for enhancing performance and perception of well-being in a healthy mammal / individual.